Education
About Us
Working with TipRanks
Follow Us
Grace Therapeutics (GRCE)
NASDAQ:GRCE
GRCE Stock Chart & Stats
$4.29
-$0.02(-0.47%)
At close: 4:00 PM EST
$4.29
-$0.02(-0.47%)
Day’s Range― - ―
52-Week Range$1.75 - $4.30
Previous CloseN/A
Volume30.96K
Average Volume (3M)58.56K
Market Cap
$66.38M
Enterprise Value$41.94M
Total Cash (Recent Filing)$18.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Jun 23, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding15,474,026
10 Day Avg. Volume55,886
30 Day Avg. Volume58,559
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.41
Price to Sales (P/S)0.00
P/FCF Ratio-1.85
Enterprise Value/Market Cap0.63
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.19K
Enterprise Value/Ebitda-5.40
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetA zero-debt balance sheet and a roughly $64.9M equity cushion materially lower solvency risk and give management flexibility to fund clinical programs or pursue partnerships. This structural strength reduces bankruptcy risk and improves negotiating leverage for non-dilutive deals over the next several quarters.
Regulatory And Clinical ProgressNDA acceptance and a set PDUFA date represent a concrete path to commercialization; positive Phase 3 results materially de-risk efficacy claims; and a U.S. patent to 2043 secures long-term exclusivity. Together these are structural assets that can enable future revenue and licensing opportunities if approval is obtained.
Improving Loss TrajectoryA clear reduction in net losses year-over-year signals improved cost discipline or operational efficiency during development. Sustained improvement in loss magnitude enhances runway extension potential, lowers near-term funding frequency needs, and demonstrates management is executing a plan to reduce burn prior to commercialization.
Bears Say
Pre-revenue Business ModelThe company remains pre-revenue, meaning it has no operating sales to cover expenses. Until regulatory approval and successful commercialization, it will rely on external capital or partners. This structural dependence raises dilution risk and makes long-term profitability contingent on successful product launch and adoption.
Persistent Negative Cash FlowConsistently negative operating and free cash flow requires ongoing financing to sustain clinical programs. Even with some improvement, a roughly -$10.1M TTM burn rate structurally limits flexibility, increases the probability of dilutive capital raises, and constrains the ability to scale commercial operations without external funding.
Very Limited Organizational ScaleAn extremely small headcount constrains internal capabilities for manufacturing, regulatory submissions, commercial launch, and scaling. Reliance on contractors and partners is structural, raising execution risk, increasing operating leverage when commercializing, and potentially slowing response times and product rollout.
Grace Therapeutics News
GRCE FAQ
What was Grace Therapeutics’s price range in the past 12 months?
Grace Therapeutics lowest stock price was $1.75 and its highest was $4.30 in the past 12 months.
What is Grace Therapeutics’s market cap?
Grace Therapeutics’s market cap is $66.38M.
When is Grace Therapeutics’s upcoming earnings report date?
Grace Therapeutics’s upcoming earnings report date is Jun 23, 2026 which is in 112 days.
How were Grace Therapeutics’s earnings last quarter?
Grace Therapeutics released its earnings results on Feb 12, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.28 by $0.14.
Is Grace Therapeutics overvalued?
According to Wall Street analysts Grace Therapeutics’s price is currently Overvalued.
Does Grace Therapeutics pay dividends?
Grace Therapeutics does not currently pay dividends.
What is Grace Therapeutics’s EPS estimate?
Grace Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Grace Therapeutics have?
Grace Therapeutics has 15,474,026 shares outstanding.
What happened to Grace Therapeutics’s price movement after its last earnings report?
Grace Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.28. Following the earnings report the stock price went down -1.671%.
Which hedge fund is a major shareholder of Grace Therapeutics?
Currently, no hedge funds are holding shares in GRCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grace Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.3%
Last 30 Days ▼ 1.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-8.10%
12-Months-Change
Fundamentals
Return on Equity
-13.15%
Trailing 12-Months
Asset Growth
1.88%
Trailing 12-Months
Company Description
Grace Therapeutics
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
GRCE Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
8.48%
Insiders
2.62% Mutual Funds
17.63% Other Institutional Investors
68.68% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---